Please use this identifier to cite or link to this item: https://doi.org/10.1158/2159-8290.CD-12-0028
DC FieldValue
dc.titleJanus kinase 3-activating mutations identifi ed in natural killer/T-cell lymphoma
dc.contributor.authorKoo, G.C.
dc.contributor.authorTan, S.Y.
dc.contributor.authorTang, T.
dc.contributor.authorPoon, S.L.
dc.contributor.authorAllen, G.E.
dc.contributor.authorTan, L.
dc.contributor.authorChong, S.C.
dc.contributor.authorOng, W.S.
dc.contributor.authorTay, K.
dc.contributor.authorTao, M.
dc.contributor.authorQuek, R.
dc.contributor.authorLoong, S.
dc.contributor.authorYeoh, K.-W.
dc.contributor.authorYap, S.P.
dc.contributor.authorLee, K.A.
dc.contributor.authorLim, L.C.
dc.contributor.authorTan, D.
dc.contributor.authorGoh, C.
dc.contributor.authorCutcutache, I.
dc.contributor.authorYu, W.
dc.contributor.authorNg, C.C.Y.
dc.contributor.authorRajasegaran, V.
dc.contributor.authorHeng, H.L.
dc.contributor.authorGan, A.
dc.contributor.authorOng, C.K.
dc.contributor.authorRozen, S.
dc.contributor.authorTan, P.
dc.contributor.authorTeh, B.T.
dc.contributor.authorLim, S.T.
dc.date.accessioned2013-07-23T09:24:54Z
dc.date.available2013-07-23T09:24:54Z
dc.date.issued2012
dc.identifier.citationKoo, G.C., Tan, S.Y., Tang, T., Poon, S.L., Allen, G.E., Tan, L., Chong, S.C., Ong, W.S., Tay, K., Tao, M., Quek, R., Loong, S., Yeoh, K.-W., Yap, S.P., Lee, K.A., Lim, L.C., Tan, D., Goh, C., Cutcutache, I., Yu, W., Ng, C.C.Y., Rajasegaran, V., Heng, H.L., Gan, A., Ong, C.K., Rozen, S., Tan, P., Teh, B.T., Lim, S.T. (2012). Janus kinase 3-activating mutations identifi ed in natural killer/T-cell lymphoma. Cancer Discovery 2 (7) : 591-597. ScholarBank@NUS Repository. https://doi.org/10.1158/2159-8290.CD-12-0028
dc.identifier.issn21598274
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/43098
dc.description.abstractThe molecular pathogenesis of natural killer/T-cell lymphoma (NKTCL) is not well understood. We conducted whole-exome sequencing and identifi ed Janus kinase 3 (JAK3) somatic-activating mutations (A572V and A573V) in 2 of 4 patients with NKTCLs. Further validation of the prevalence of JAK3 mutations was determined by Sanger sequencing and high-resolution melt (HRM) analysis in an additional 61 cases. In total, 23 of 65 (35.4%) cases harbored JAK3 mutations. Functional characterization of the JAK3 mutations support its involvement in cytokine-independent JAK/ STAT constitutive activation leading to increased cell growth. Moreover, treatment of both JAK3-mutant and wild-type NKTCL cell lines with a novel pan-JAK inhibitor, CP-690550, resulted in dose-dependent reduction of phosphorylated STAT5, reduced cell viability, and increased apoptosis. Hence, targeting the deregulated JAK/STAT pathway could be a promising therapy for patients with NKTCLs. SIGNIFICANCE: Gene mutations causing NKTCL have not been fully identifi ed. Through exome sequencing, we identifi ed activating mutations of JAK3 that may play a signifi cant role in the pathogenesis of NKTCLs. Our fi ndings have important implications for the management of patients with NKTCLs. © 2012 American Association for Cancer Research.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1158/2159-8290.CD-12-0028
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.contributor.departmentCOMPUTER SCIENCE
dc.description.doi10.1158/2159-8290.CD-12-0028
dc.description.sourcetitleCancer Discovery
dc.description.volume2
dc.description.issue7
dc.description.page591-597
dc.identifier.isiut000306365800038
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

163
checked on Dec 1, 2020

WEB OF SCIENCETM
Citations

138
checked on Nov 23, 2020

Page view(s)

210
checked on Nov 24, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.